0001437749-26-009797 | 10-K | XBRL Viewer | Seastar Medical Holding Corp

Accounts and Nontrade Receivable [Text Block]

Note 4. Trade Accounts Receivable

The table below presents the opening and closing balances of accounts receivable, on a gross and net basis, with the total change in expected credit losses:

($ in thousands)	Accounts Receivable, Gross		Expected Credit Losses			Accounts Receivable, Net
December 31, 2024	$	112	$	—		$	112
Changes in accounts receivable		128		(3	)		125
December 31, 2025	$	240	$	(3	)	$	237

Note 15 - Segment Reporting

12 Months Ended

Dec. 31, 2025

Segment Reporting Disclosure [Text Block]

Note 15. Segment Reporting

The Company is comprised of a single reportable segment, its Device Segment. This organizational structure aligns with how our Chief Operating Decision Maker (“CODM”), the Chief Executive Officer, manages the Company’s business, including resource allocation and performance assessment. The Company is focused entirely on the development, regulatory approval and commercialization of the Company’s adult and pediatric Selective Cytopheretic Devices (SCDs). The Company had a total of 17 employees at December 31, 2025, and total assets of $14.2 and $4.7 million, as of December 31, 2025 and 2024, respectively.

For segment reporting purposes, the CODM uses operating profit/(loss) to evaluate segment performance and allocate resources. As a Company that only recently began limited commercial sales of QUELIMMUNE, the CODM is primarily focused on evaluating the overall spending for research and development activities needed to fund further development of the SCDs, and general and administrative activities incurred to support the research and development activities of the Company. Accounting policies associated with the Company’s sole segment are the same as those described in Note 1.

All of the Company’s sales are located within the United States. As of the date of this report, the Company has obtained regulatory approval for commercial sales in the U.S. of QUELIMMUNE from the FDA. The Company does not have any inter-entity sales or transfers.

The following table represents the Company’s sole segment’s operating results for the years ended December 31, 2025 and 2024, respectively.

	*Year Ended December 31,*
	*2025*			*2024*

Net Revenue	$	1,234		$	135
Cost of goods sold		53			—
Gross profit	$	1,181		$	135
Operating expenses
Research and development		7,518			9,105
General and administrative		5,838			8,872
Total operating expenses	$	13,356		$	17,977
Loss from operations	$	(12,175	)	$	(17,842	)

The above table excludes non-operating other income/expense, net, consisting of interest expense, interest income, and gains and losses from changes in the fair value of liability classified financial instruments such as liability classified warrants and convertible debt.

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Note 5 - Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Accrued Liabilities [Table Text Block]

($ in thousands)	*December 31, 2025*		*December 31, 2024*
Accrued research and development	$	1,525	$	1,023
Accrued bonus		150		1,391
Accrued director compensation		70		391
Other		523		383
Total accrued expenses	$	2,268	$	3,188

Note 5 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Accrued research and development	$ 1,525	$ 1,023
Accrued bonus	150	1,391
Accrued director compensation	70	391
Other	523	383
Total accrued expenses	$ 2,268	$ 3,188

Note 13 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	*Year Ended December 31, 2025*
	*Amount*			*Percent*
Federal tax at statutory rate	$	(2,551	)	$	21.00	%
State Tax net of federal benefits		4			-0.03	%
R&D tax credit		(275	)		2.27	%
Nontaxable or nondeductible items		(3	)		0.01	%
Change in Valuation Allowance		2,740			-22.44	%
Other Adjustments		88			-0.85	%
Tax Expense	$	3		$	-0.03	%

	*Year Ended December 31, 2024*
	*Amount*			*Percentages*
Federal tax at statutory rate	$	(5,214	)	$	21.00	%
State income tax		776			-3.12	%
R&D tax credit		(197	)		0.79	%
Stock compensation expense		18			-0.07	%
Unrealized gains and losses, net, for liability classified warrants		146			-0.59	%
Unrealized gains and losses, net, for convertible debt		1,291			-5.20	%
Adjustment to prior period federal deferred tax assets		95			-0.38	%
Non-deductible expenses		6			-0.03	%
Other		172			-0.68	%
Change in valuation allowance		2,910			-11.72	%
Total effective income tax rate	$	3		$	0.00	%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	*December 31,*			*December 31,*
	*2025*			*2024*
Deferred tax assets:
Net operating losses	$	26,779		$	23,936
Finance charges and origination fees		—			133
Accrued compensation		141			314
Stock-based compensation		87			47
Section 174 research and development capitalization		2,099			2,771
Section 59(e) research and development capitalization		1,292			—
Capitalized start-up fees		197			209
Tax credits		1,394			1,103
Total deferred tax assets		31,989			28,513
Valuation allowance		(31,989	)		(28,513	)
Net deferred tax assets	$	—		$	—

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	*Uncertain Tax Position*
Balance as of December 31, 2024	$	944
Increase in prior year		—
Increase in current year		127
Balance as of December 31, 2025	$	1,071

Note 3 - Revenues and Contract Obligations (Details Textual) - USD ($)		1 Months Ended	12 Months Ended
	Oct. 20, 2024	Dec. 31, 2022	Dec. 31, 2025	Dec. 31, 2024
Contract with Customer, Liability, Consideration Received			$ 0	$ 450,000
Revenue from Contract with Customer, Excluding Assessed Tax			1,234,000	135,000
Pediatric SCDs [Member]
Revenue from Contract with Customer, Excluding Assessed Tax			$ 1,200,000	100,000
License and Distribution Agreement [Member] \| Pediatric SCDs [Member]
Unrecognizable Revenue				$ 100,000
License and Distribution Agreement [Member] \| Nuwellis [Member]
Proceeds from Upfront Licensing Payment		$ 100,000
Contract with Customer, Liability, Consideration Received	$ 550	550,000
Contract with Customer, Refund Liability, Additional Return	350
Contract with Customer, Refund Liability	$ 900,000
License and Distribution Agreement [Member] \| Nuwellis [Member] \| Regulatory Milestone [Member]
Milestone Payments		450,000
License and Distribution Agreement [Member] \| Nuwellis [Member] \| Sales Based Milestone [Member]
Milestone Payments		$ 300,000

Note 15 - Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	*Year Ended December 31,*
	*2025*			*2024*

Net Revenue	$	1,234		$	135
Cost of goods sold		53			—
Gross profit	$	1,181		$	135
Operating expenses
Research and development		7,518			9,105
General and administrative		5,838			8,872
Total operating expenses	$	13,356		$	17,977
Loss from operations	$	(12,175	)	$	(17,842	)

Note 14 - Net Loss Per Share (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	As of December 31,
	2025		2024
Liability classified warrants		24,952		24,952
Equity classified warrants		2,674,972		211,031
Employee based options to purchase common stock		1,812		22,653
Unvested employee based restricted stock units		25,870		40,068
Total		2,727,606		298,704

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	*Year Ended December 31,*
	*2025*			*2024*
Net loss	$	(12,150	)	$	(24,830	)
Weighted-average shares outstanding - basic and diluted		2,073,087			374,356
Basic and diluted net loss per share	$	(5.86	)	$	(66.33	)

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
Cybersecurity Risk Management and Strategy Disclosure	Dec. 31, 2025
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	*Item 1C.* Cybersecurity.** Our Board considers cybersecurity and other information technology risks as part of its risk management and compliance oversight function. The Board oversees management’s implementation of our cybersecurity risk management processes and receives reports from management on our cybersecurity risks annually. In addition, management updates the Board, as necessary, regarding any significant cybersecurity incidents. The Board receives briefings from management on our cyber risk management processes, and it receives presentations on cybersecurity topics from management as part of the Board’s risk oversight function and continuing education on topics that impact public companies. We have an information security program designed to identify, protect, detect and respond to and manage reasonably foreseeable cybersecurity risks and threats. To protect our information systems from cybersecurity threats, we use various security tools that help prevent, identify, escalate, investigate, resolve and recover from identified vulnerabilities and security incidents in a timely manner. These include, but are not limited to, internal reporting, monitoring and detection tools. We regularly assess risks from cybersecurity and technology threats and monitor our information systems for potential vulnerabilities. We utilize third-party information technology services help identify, measure, and prioritize cybersecurity and technology risks, as well as to develop related security controls and safeguards. While we have not, as of the date of this Form 10-K, experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations, there can be no guarantee that we will not experience such an incident in the future. Such incidents, whether or not successful, could result in our incurring significant costs related to, for example, rebuilding our internal systems, implementing additional threat protection measures, defending against litigation, responding to regulatory inquiries or actions, paying damages, providing customers with incentives to maintain a business relationship with us, or taking other remedial steps with respect to third parties, as well as incurring significant reputational harm. In addition, these threats are constantly evolving, thereby increasing the difficulty of successfully defending against them or implementing adequate preventative measures.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	We have an information security program designed to identify, protect, detect and respond to and manage reasonably foreseeable cybersecurity risks and threats. To protect our information systems from cybersecurity threats, we use various security tools that help prevent, identify, escalate, investigate, resolve and recover from identified vulnerabilities and security incidents in a timely manner. These include, but are not limited to, internal reporting, monitoring and detection tools. We regularly assess risks from cybersecurity and technology threats and monitor our information systems for potential vulnerabilities. We utilize third-party information technology services help identify, measure, and prioritize cybersecurity and technology risks, as well as to develop related security controls and safeguards.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]	While we have not, as of the date of this Form 10-K, experienced a cybersecurity threat or incident that resulted in a material adverse impact to our business or operations, there can be no guarantee that we will not experience such an incident in the future. Such incidents, whether or not successful, could result in our incurring significant costs related to, for example, rebuilding our internal systems, implementing additional threat protection measures, defending against litigation, responding to regulatory inquiries or actions, paying damages, providing customers with incentives to maintain a business relationship with us, or taking other remedial steps with respect to third parties, as well as incurring significant reputational harm. In addition, these threats are constantly evolving, thereby increasing the difficulty of successfully defending against them or implementing adequate preventative measures.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Board considers cybersecurity and other information technology risks as part of its risk management and compliance oversight function. The Board oversees management’s implementation of our cybersecurity risk management processes and receives reports from management on our cybersecurity risks annually. In addition, management updates the Board, as necessary, regarding any significant cybersecurity incidents. The Board receives briefings from management on our cyber risk management processes, and it receives presentations on cybersecurity topics from management as part of the Board’s risk oversight function and continuing education on topics that impact public companies.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Note 8 - Warrants (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	December 31, 2025		December 31, 2024
*Liability Classified Warrants*
Private Placement Warrants		22,952		22,952
PIPE Investor Warrants		2,000		2,000
*Subtotal*		24,952		24,952

*Equity Classified Warrants*
August 2025 Warrants		530,779		—
July 2025 Warrants		560,944		—
June 2025 Warrants		994,616		—
February 2025 Warrants		377,648		—
July 2024 Warrants		101,422		101,422
January 2024 Warrants		67,213		67,213
Public Stockholders’ Warrants		42,200		42,200
Legacy Warrants		150		196
*Subtotal*		2,674,972		211,031
*Grand Total*		2,699,924		235,983

Schedule of Inputs for Warrant Tranches [Table Text Block]

December 31, 2025	*Warrant Share Equivalents*		*Weighted-Average Strike Price*		*Weighted-Average Time to Expiration*
*Liability Classified Warrants*
Private Placement Warrants		22,952	$	2,875.00		1.82
PIPE Investor Warrants		2,000	$	2,875.00		1.82

*Equity Classified Warrants*
August 2025 Warrants		530,779	$	7.85		4.61
July 2025 Warrants		560,944	$	6.59		4.61
June 2025 Warrants		994,616	$	6.57		3.15
February 2025 Warrants		377,648	$	17.34		4.24
July 2024 Warrants		101,422	$	107.23		3.53
January 2024 Warrants		67,213	$	23.82		3.44
Public Stockholders’ Warrants		42,200	$	2,875.00		2.33
Legacy SeaStar Inc. Warrants		150	$	2,500.00		1.17

December 31, 2024	*Warrant Share Equivalents*		*Weighted-Average Strike Price*		*Weighted-Average Time to Expiration*
*Liability Classified Warrants*
Private Placement Warrants		22,952	$	2,875.00		2.82
PIPE Investor Warrants		2,000	$	2,875.00		2.82

*Equity Classified Warrants*
July 2024 Warrants		101,422	$	107.20		4.53
January 2024 Warrants		67,213	$	208.27		3.01
Public Stockholders’ Warrants		42,200	$	2,875.00		2.82
Legacy SeaStar Inc. Warrants		196	$	2,500.00		1.38

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]

	*August 2025 Warrants*		*July 2025 Warrants*			*June 2025 Warrants*			*February 2025 Warrants*			*Legacy Warrants*
Outstanding as of December 31, 2024		—		—			—			—			196
Issuance		530,779		601,067			1,395,693			659,289			—
Exercised		—		(40,123	)		(401,077	)		(281,641	)		—
Forfeited / cancelled		—		—			—			—			(46	)
Outstanding as of December 31, 2025		530,779		560,944			994,616			377,648			150

Note 3 - Revenues and Contract Obligations - Summary of Revenues and Contract Obligations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Contract liabilities, beginning of period	$ 0	$ 100
Consideration received	0	450
Consideration refunded	0	(550)
Contract liabilities, end of period	$ 0	$ 0

Note 7 - Equity Transactions (Details Textual) - USD ($) $ / shares in Units, $ in Thousands					1 Months Ended	8 Months Ended		12 Months Ended		16 Months Ended
	Aug. 01, 2025	Jul. 11, 2025	Apr. 25, 2025	Feb. 03, 2025	Jun. 30, 2025	Dec. 31, 2025	Sep. 30, 2025	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2025	Feb. 28, 2025	Jun. 07, 2024	Jan. 31, 2024	Oct. 28, 2022
Common Stock, Par or Stated Value Per Share (in dollars per share)						$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001		$ 0.0001
Proceeds from Issuance of Common Stock								$ 16,126	$ 17,441
June 2025 Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					43,077
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 8.13
Common Stock Purchasable, Percent of Shares Placed in Offering					125.00%
February 2025 Pre-funded Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)							0
Class of Warrant or Right, Exercised During Period (in shares)							281,642
January 2024 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						67,213		67,213	67,213	67,213	65,046
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 207.6		$ 23.82		$ 23.82	$ 208.27	$ 23.82			$ 17
August 2025 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	496,055
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Offering Price per Share (in dollars per share)	$ 8.87
Proceeds from Issuance or Sale of Equity	$ 4,400
Equity Offering, Issuance Costs	$ 500
Aggregate Cash Fee Percentage	7.00%
Management Fee, Percentage of Aggregate Gross Proceeds	1.00%
August 2025 Offering [Member] \| August 2025 Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	496,055
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 7.62
August 2025 Offering [Member] \| August 2025 Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	34,724
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 11.08
Percentage of Placement Warrant Exercise Price Equal to Offering Price	125.00%
July 2025 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)		484,124
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001
Offering Price per Share (in dollars per share)		$ 7.63
Proceeds from Issuance or Sale of Equity		$ 4,000
Equity Offering, Issuance Costs		$ 400
Aggregate Cash Fee Percentage		7.00%
Management Fee, Percentage of Aggregate Gross Proceeds		1.00%
July 2025 Offering [Member] \| July 2025 Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		40,124
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.01
July 2025 Offering [Member] \| July 2025 Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		524,247
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 6.378
July 2025 Offering [Member] \| July 2025 Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		36,698
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 9.538
July 2025 Offering [Member] \| July 2024 Placement Agent Warrants [Member]
Percentage of Placement Warrant Exercise Price Equal to Offering Price		125.00%
June 2025 Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)					493,539
Proceeds from Issuance or Sale of Equity					$ 4,000
Equity Offering, Issuance Costs					$ 500
Aggregate Cash Fee Percentage					7.00%
Management Fee, Percentage of Aggregate Gross Proceeds					1.00%
June 2025 Offering [Member] \| June 2025 Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					121,847
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 0.001
Class of Warrant or Right, Issued During Period (in shares)					121,847
June 2025 Offering [Member] \| Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					615,385
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 6.5
Class of Warrant or Right, Issued During Period (in shares)					615,385
Class of Warrant or Right, Outstanding (in shares)						574,616		574,616		574,616
Class of Warrant or Right, Exercised During Period (in shares)								40,770
June 2025 Offering [Member] \| Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					615,385
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 6.5
Class of Warrant or Right, Outstanding (in shares)					615,385	376,924		376,924		376,924
Class of Warrant or Right, Exercised During Period (in shares)								238,462
Q1 2025 Securities Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)				71,300
Proceeds from Issuance or Sale of Equity				$ 6,000
Equity Offering, Issuance Costs				$ 500
Q1 2025 Securities Purchase Agreement [Member] \| February 2025 Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				281,642
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.001
Q1 2025 Securities Purchase Agreement [Member] \| February 2025 Common Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				352,942
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 17
Q1 2025 Securities Purchase Agreement [Member] \| February 2025 Placement Agent Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				24,706
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 21.25
At-the-Market Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)								900,000		1,100,000
Equity Offering, Issuance Costs										$ 400
Proceeds from Issuance of Common Stock								$ 5,900		$ 10,400
Payments of Stock Issuance Costs								200
Standby Equity Purchase Agreement [Member]
Stock Issued During Period, Value, New Issues								$ 42
Standby Equity Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)			23,641			8,000
Proceeds from Issuance or Sale of Equity						$ 40
Share Issued, Price Per Share, Percentage of Sale Price			97.00%
Ownership of Outstanding Voting Power, Percentage			9.99%
Stock Issued During Period, Value, New Issues			$ 300
Standby Equity Purchase Agreement [Member] \| Lincoln Park Capital Fund, LLC [Member] \| Maximum [Member]
Share Issuable, Maximum Value			$ 15,000

Note 4 - Trade Accounts Receivable (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

($ in thousands)	Accounts Receivable, Gross		Expected Credit Losses			Accounts Receivable, Net
December 31, 2024	$	112	$	—		$	112
Changes in accounts receivable		128		(3	)		125
December 31, 2025	$	240	$	(3	)	$	237

Note 13 - Income Taxes - Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Net operating losses	$ 26,779	$ 23,936
Finance charges and origination fees	0	133
Accrued compensation	141	314
Stock-based compensation	87	47
Section 174 research and development capitalization	2,099	2,771
Section 59(e) research and development capitalization	1,292	0
Capitalized start-up fees	197	209
Tax credits	1,394	1,103
Total deferred tax assets	31,989	28,513
Valuation allowance	(31,989)	(28,513)
Net deferred tax assets	$ 0	$ 0

Note 15 - Segment Reporting (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Assets	$ 14,158	$ 4,658
Number of Reportable Segments	1

Amount of asset recognized for present right to economic benefit.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 64
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481620/480-10-55-64

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Note 14 - Net Loss Per Share

12 Months Ended

Dec. 31, 2025

Earnings Per Share [Text Block]

Note 14. Net Loss Per Share

Basic net loss per common share is calculated by dividing the net loss by the weighted-average number of common shares outstanding during the period, including vested restricted stock units for which common shares have not yet been issued, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the warrants, common stock options, and unvested restricted stock units are considered to be potentially dilutive securities. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods.

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive:

	As of December 31,
	2025		2024
Liability classified warrants		24,952		24,952
Equity classified warrants		2,674,972		211,031
Employee based options to purchase common stock		1,812		22,653
Unvested employee based restricted stock units		25,870		40,068
Total		2,727,606		298,704

The following table presents the calculation of basic and diluted net loss per share (in thousands except share and per share information):

	*Year Ended December 31,*
	*2025*			*2024*
Net loss	$	(12,150	)	$	(24,830	)
Weighted-average shares outstanding - basic and diluted		2,073,087			374,356
Basic and diluted net loss per share	$	(5.86	)	$	(66.33	)

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash Equivalents, at Carrying Value	$ 0	$ 0
Accounts Receivable, Allowance for Credit Loss, Current	3	0
Cost of Product and Service Sold	53	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments	0
Funded Research and Development, Reimbursed Expenses	$ 400

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References + Details

Note 14 - Net Loss Per Share - Summary of Dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Antidilutive securities (in shares)	2,727,606	298,704
Liability Classified Warrants [Member]
Antidilutive securities (in shares)	24,952	24,952
Equity Classified Warrants [Member]
Antidilutive securities (in shares)	2,674,972	211,031
Share-Based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	1,812	22,653
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	25,870	40,068

Note 8 - Warrants - Summary of Warrant Activity (Details)	12 Months Ended
	Dec. 31, 2025 shares
August 2025 Warrants [Member]
Outstanding (in shares)	0
Issuance (in shares)	530,779
Exercised (in shares)	0
Forfeited / cancelled (in shares)	0
Outstanding (in shares)	530,779
July 2025 Warrants [Member]
Outstanding (in shares)	0
Issuance (in shares)	601,067
Exercised (in shares)	(40,123)
Forfeited / cancelled (in shares)	0
Outstanding (in shares)	560,944
June 2025 Warrants [Member]
Outstanding (in shares)	0
Issuance (in shares)	1,395,693
Exercised (in shares)	(401,077)
Forfeited / cancelled (in shares)	0
Outstanding (in shares)	994,616
February 2025 Warrants [Member]
Outstanding (in shares)	0
Issuance (in shares)	659,289
Exercised (in shares)	(281,641)
Forfeited / cancelled (in shares)	0
Outstanding (in shares)	377,648
Legacy Warrants [Member]
Outstanding (in shares)	196
Issuance (in shares)	0
Exercised (in shares)	0
Forfeited / cancelled (in shares)	(46)
Outstanding (in shares)	150

Note 7 - Equity Transactions

12 Months Ended

Dec. 31, 2025

Equity [Text Block]

Note 7. Equity Transactions

August 2025 Offering

On August 1, 2025, the Company closed on a registered direct offering with certain institutional investors (the “August 2025 Offering”), pursuant to which the Company sold and issued to the Purchasers, (i) 496,055 shares of the Company’s common stock par value $0.0001 per share and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 496,055 shares of Common Stock (the “August 2025 Common Warrants”) at an exercise price of $7.62 per share. The combined offering price for each share of common stock and accompanying August 2025 Common Warrant was $8.87. The August 2025 Common Warrants are exercisable upon issuance and will expire on August 12, 2030.

The Company received aggregate gross proceeds from the August 2025 Offering of approximately $4.4 million before deducting fees of approximately $0.5 million in offering costs comprised of a cash fee of 7.00%, a management fee of 1.00%, legal fees and other fees. Also in connection with the August 2025 Offering, the Company agreed to issue to the placement agent or its designees warrants (the “August 2025 Placement Agent Warrants”) to purchase up to an aggregate of 34,724 shares of common stock. The August 2025 Placement Agent Warrants have an exercise price of $11.08 per share (which represents 125% of the offering price per share of common stock and accompanying August 2025 Common Warrant), are exercisable upon issuance and will expire on July 31, 2030.

The August 2025 Common Warrants and August 2025 Placement Agent Warrants collectively herein are referred to as the “August 2025 Warrants”. No August 2025 Warrants have been exercised and all August 2025 Warrants remain outstanding as of December 31, 2025.

In accordance with ASC 815-40, Derivatives and Hedging-Contracts in Entity’s own Equity, the Company determined that all of the August 2025 Warrants issued in connection with the August 2025 Offering met the conditions for equity classification and were included as a component of stockholders’ equity/(deficit).

July 2025 Offering

On July 11, 2025, the Company closed on a registered direct offering with certain institutional investors (the “July 2025 Offering”), pursuant to which the Company sold and issued to the Purchasers, (i) 484,124 shares of the Company’s common stock par value $0.0001 per share and pre-funded warrants to purchase up to 40,124 shares of common stock (the “July 2025 Pre-Funded Warrants”) at an exercise price of $0.01 per share (the July 2025 Pre-Funded Warrants were fully exercised concurrent with the July 2025 Offering), and (ii) in a concurrent private placement, warrants to purchase up to an aggregate of 524,247 shares of common stock (the “July 2025 Common Warrants”) at an exercise price of $6.378 per share. The combined offering price for each share of common stock and accompanying July 2025 Common Warrant was $7.63. The July 2025 Common Warrants are exercisable upon issuance and will expire on August 12, 2030.

The Company received aggregate gross proceeds from the July 2025 Offering of approximately $4.0 million before deducting fees paid of $0.4 million in offering costs comprised of a cash fee of 7.00%, a management fee of 1.00%, legal fees and other fees. Also in connection with the July 2025 Offering, the Company agreed to issue to the placement agent or its designees warrants (the “July 2025 Placement Agent Warrants”) to purchase up to an aggregate of 36,698 shares of common stock. The July 2025 Placement Agent Warrants have an exercise price of $9.538 per share (which represents 125% of the offering price per share of common stock and accompanying July 2025 Common Warrant), are exercisable upon issuance and will expire on July 10, 2030.

The July 2025 Common Warrants and July 2025 Placement Agent Warrants collectively herein are referred to as the “July 2025 Warrants”. No July 2025 Warrants have been exercised and all July 2025 Warrants remain outstanding as of December 31, 2025.

In accordance with ASC 815-40, Derivatives and Hedging-Contracts in Entity’s own Equity, the Company determined that all of the warrants issued in connection with the July 2025 Offering met the conditions for equity classification and were included as a component of stockholders’ equity/(deficit)

June 2025 Offering

In June 2025, the Company did a best efforts public offering (the “June 2025 Offering”) pursuant to which the Company issued an aggregate of (i) 493,539 shares of the Company's common stock, (ii) 121,847 pre-funded warrants to purchase up to 121,847 shares of common stock (the “June 2025 Pre-Funded Warrants”) with an exercise price of $0.001, (iii) 615,385 Series A warrants to purchase up to 615,385 shares of common stock with an exercise price of $6.50 (the “June 20205 Series A Warrants”), and (iv) 615,385 Series B warrants to purchase up to 615,385 shares of common stock at an exercise price of $6.50 (the “June 2025 Series B Warrants”). All 121,847 June 2025 Pre-Funded Warrants were exercised as of December 31, 2025.

The Company received aggregate gross proceeds from the June 2025 Offering of approximately $4.0 million, before deducting approximately $0.5 million in offering costs comprised of cash fee of 7.00%, a management fee of 1.00%, legal fees and other fees. Also in connection with the June 2025 Offering, the Company agreed to issue to the placement agent or its designees warrants (the “June 2025 Placement Agent Warrants”) to purchase up to an aggregate of 43,077 shares of common stock. The June 2025 Placement Agent Warrants have an exercise price of $8.13 per share (which represents 125% of the offering price per share of common stock and accompanying June 2025 Series A and Series B Warrants), are exercisable upon issuance and will expire on June 20, 2030. No June 2025 Placement Warrants have been exercised and all June 2025 Placement Warrants remain outstanding as of December 31, 2025.

The June 2025 Series A Warrants and June 2025 Series B Warrants were immediately exercisable with the June 2025 Series A warrants expiring on June 23, 2030 and the June 2025 Series B Warrants expiring on December 23, 2026. During the year ended December 31, 2025, 40,770 and 238,462 Series A June 2025 Warrants and Series B June 2025 Warrants have been exercised, respectively and 574,616 and 376,924 Series A June 2025 Warrants and Series B June 2025 Warrants remain outstanding, respectively, as of December 31, 2025.

In accordance with ASC 815-40, Derivatives and Hedging-Contracts in Entity’s own Equity, the Company determined that all the different warrants issued or amended in connection with the June 2025 Offering met the conditions for equity classification and were included as a component of stockholders’ equity/(deficit).

February 2025 Offering

In January 2025, the Company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which the Company issued on February 3, 2025, to the investor, (i) in a registered direct offering, 71,300 shares of the Company’s common stock, and pre-funded warrants to purchase 281,642 shares of common stock (the “February 2025 Pre-Funded Warrants”) with an exercise price of $0.001 per share, and (ii) in a concurrent private placement, warrants (the "February 2025 Common Warrants") to purchase 352,942 shares of common stock with an exercise price of $17.00 (the “February 2025 Offering”).

The Company received aggregate gross proceeds from the February 2025 Offering of approximately $6.0 million, before deducting approximately $0.5 million of fees and other estimated offering expenses payable by the Company. The February 2025 Pre-Funded Warrants did not have a set expiration and were exercisable upon issuance and at any time until all of the February 2025 Pre-Funded Warrants were exercised in full. During the year ended December 31, 2025, a total of 281,642 February 2025 Pre-Funded Warrants were exercised, and no February 2025 Pre-Funded Warrants remain outstanding.

The February 2025 Common Warrants became exercisable on March 28, 2025, the effective date of stockholder approval for the issuance of the shares of common stock issuable upon exercise of the warrants and expire on March 28, 2030.

Prior to their exercise, the February 2025 Pre-Funded Warrants had dividend participation rights, and any unexercised pre-funded warrants are included in the Company's weighted-average shares outstanding for calculation of the Company's net loss per share.

In connection with the February 2025 Offering, the Company amended the exercise price of the January 2024 Series A and January 2024 Series B Common Warrants (collectively the “January 2024 Warrants”), issued in a previous financing transaction with the same institutional investor in January 2024, to $17.00 from the original exercise price of $207.60. Furthermore, the expiration date of all 65,046 January 2024 Warrants was extended to January 30, 2029, upon stockholder approval on March 28, 2025. No January 2024 Warrants have been exercised and all January 2024 Warrants remain outstanding as of December 31, 2025.

The Company issued 24,706 warrants to its placement agent (the "February 2025 PA Warrants") to purchase shares of the Company's common stock at an exercise price of $21.25. The February 2025 PA Warrants were exercisable upon issuance and expire on January 30, 2029. The February 2025 PA Warrants and February 2025 Common Warrants are herein defined as the "February 2025 Warrants". No February 2025 Warrants have been exercised and all February 2025 Warrants remain outstanding as of December 31, 2025.

In accordance with ASC 815-40, Derivatives and Hedging-Contracts in Entity’s own Equity, the Company determined that all the different warrants issued or amended in connection with the February 2025 Offering met the conditions for equity classification and were included as a component of stockholders’ equity/(deficit).

At-The-Market Offering

On August 20, 2024, the Company entered into an At-The-Market Offering Agreement (the “ATM Agreement”) with Wainwright as sales agent, to sell shares of its common stock, from time to time, through an “at the market offering” program under which Wainwright will act as sales agent. The sales, if any, of the Company’s Common Stock made under the ATM Agreement will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on or through the Nasdaq Capital Market or on any other existing trading market for the Company’s common stock (the “ATM”).

Through December 31, 2025, the Company has raised approximately $10.4 million, net of offering costs of $0.4 million utilizing the ATM since inception in August 2024, issuing approximately 1.1 million shares of the Company’s Common Stock. During the year ended December 31, 2025, the Company raised approximately $5.9 million, net of offering costs of $0.2 million, issuing approximately 0.9 million shares of the Company's common stock.

Standby Equity Purchase Agreement

On April 25, 2025, the Company entered into a standby equity purchase agreement (“Common Stock Purchase Agreement”) and related registration rights agreement (the “Registration Rights Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), collectively the “SEPA”. Pursuant to the Common Stock Purchase Agreement, the Company has the right, but not the obligation, to direct Lincoln Park to purchase up to $15.0 million in aggregate gross purchase price of newly issued shares of Common Stock, subject to certain limitations and conditions as described below (the “SEPA Program”) at a purchase price equal to 97% of the lesser of (i) the lowest sale price of the common stock on the purchase date or (ii) average of the three lowest closing sale prices of the common stock over the last ten business days prior to the purchase date.

The Company controls the timing and amount of any sales to Lincoln Park, which depend on a variety of factors including, among other things, market conditions, the trading price of the Company’s common stock, and determinations by the Company as to appropriate sources of funding for its business and operations. However, Lincoln Park’s obligation to purchase shares is subject to certain conditions, including the daily trading volume of the Company’s stock. In all instances, the Company may not sell shares of Common Stock under the Purchase Agreement if it would result in Lincoln Park and its affiliate beneficially owning more than 9.99% of outstanding voting power or shares of the Common Stock at any one point in time.

As part of the SEPA, the Company agreed to pay Lincoln Park 23,641 shares of the Company’s common stock, valued at approximately $0.3 million on the date of issuance, April 25, 2025 (the “Commitment Fee”).

The Company evaluated the contract that includes the right to require Lincoln Park to purchase shares of common stock in the future (“put right”) considering the guidance in ASC 815-40, Derivatives and Hedging — Contracts on an Entity’s Own Equity and concluded that it is an equity-linked contract that does not qualify for equity classification, and therefore requires fair value accounting. The Company analyzed the terms of the freestanding put right and concluded that it has an immaterial value at the issuance date of April 25, 2025, and as of December 31, 2025.

Through December 31, 2025, the Company raised approximately $40 thousand and issued 8,000 shares of the Company's common stock.

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Note 6 - Notes Payable (Details Textual) - Financing of Insurance Policy Premiums [Member] - USD ($) $ in Millions	Oct. 31, 2025	Oct. 31, 2024
Debt Instrument, Face Amount	$ 0.7	$ 0.7
Debt Instrument, Interest Rate, Stated Percentage	7.94%	8.44%

Note 12 - Fair Value Measurements - Summary of Liability Classified Warrants (Details) - Liability Classified Warrants [Member]	Dec. 31, 2025	Dec. 31, 2024
Measurement Input, Price Volatility [Member]
Measurement input	1.30
Measurement Input, Price Volatility [Member] \| Minimum [Member]
Measurement input		1.30
Measurement Input, Expected Term [Member]
Measurement input	1.825
Measurement Input, Expected Term [Member] \| Minimum [Member]
Measurement input		2.825
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.0348
Measurement Input, Risk Free Interest Rate [Member] \| Minimum [Member]
Measurement input		0.0427
Measurement Input, Expected Dividend Rate [Member]
Measurement input	0
Measurement Input, Expected Dividend Rate [Member] \| Minimum [Member]
Measurement input		0
Measurement Input, Share Price [Member]
Measurement input	2.4
Measurement Input, Share Price [Member] \| Minimum [Member]
Measurement input		1.94
Measurement Input, Strike Price [Member]
Measurement input	2,875
Measurement Input, Strike Price [Member] \| Minimum [Member]
Measurement input		287.5

Note 10 - Stock-based Compensation Awards - Summary of Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
The 2022 Omnibus Equity Incentive Plan [Member]
Outstanding, number (in shares)	1,315
Outstanding, weighted-average exercise price (in dollars per share)	$ 460
Outstanding, intrinsic value	$ 0	$ 0
Outstanding, weighted-average remaining contractual life (Year)	7 years 2 months 12 days	8 years 2 months 12 days
Exercised, number (in shares)	0
Exercised, weighted-average exercise price (in dollars per share)
Exercised, intrinsic value
Issued, number (in shares)	0
Issued, weighted average exercise price (in dollars per share)
Forfeited / cancelled, number (in shares)	(192)
Forfeited / cancelled, weighted average exercise price (in dollars per share)
Outstanding, number (in shares)	1,123	1,315
Outstanding, weighted-average exercise price (in dollars per share)	$ 460	$ 460
Vested and exercisable, number (in shares)	1,123
Vested and exercisable, weighted-average exercise price (in dollars per share)	$ 460
Vested and exercisable, intrinsic value	$ 0
Vested and exercisable, weighted-average remaining contractual life (Year)	7 years 2 months 12 days
The 2019 Omnibus Incentive Plan [Member]
Outstanding, number (in shares)	885
Outstanding, weighted-average exercise price (in dollars per share)	$ 443
Outstanding, intrinsic value	$ 0
Outstanding, weighted-average remaining contractual life (Year)	4 years 4 months 24 days	5 years 6 months
Exercised, number (in shares)	0
Exercised, weighted-average exercise price (in dollars per share)
Exercised, intrinsic value
Issued, number (in shares)	0
Issued, weighted average exercise price (in dollars per share)
Forfeited / cancelled, number (in shares)	(196)
Forfeited / cancelled, weighted average exercise price (in dollars per share)
Outstanding, number (in shares)	689	885
Outstanding, weighted-average exercise price (in dollars per share)	$ 533	$ 443
Vested and exercisable, number (in shares)	689
Vested and exercisable, weighted-average exercise price (in dollars per share)	$ 533
Vested and exercisable, intrinsic value	$ 0
Vested and exercisable, weighted-average remaining contractual life (Year)	4 years 4 months 24 days

Note 12 - Fair Value Measurements - Summary of Level 3 Input Changes (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Liability classified warrants	$ 0	$ 0
Fair Value, Inputs, Level 1 [Member]
Liability classified warrants	0	0
Fair Value, Inputs, Level 2 [Member]
Liability classified warrants	1	33
Fair Value, Inputs, Level 3 [Member]
Liability classified warrants	1	33
Liability Classified Warrants [Member]
Liability classified warrants	$ 0	0
Liability Classified Warrants [Member] \| Fair Value, Inputs, Level 1 [Member]
Liability classified warrants		0
Liability Classified Warrants [Member] \| Fair Value, Inputs, Level 2 [Member]
Liability classified warrants		33
Liability Classified Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Liability classified warrants		$ 33

Note 10 - Stock-Based Compensation Awards (Details Textual) - The 2022 Omnibus Equity Incentive Plan [Member] - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Dec. 31, 2025
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	1 year
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	4 years

Note 6 - Notes Payable

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Text Block]

Note 6. Notes Payable

Notes payable consisted of the following as of December 31, 2025 and 2024, respectively:

($ in thousands)	*December 31, 2025*			*December 31, 2024*
Insurance financing	$	525		$	574
Less current portion		(525	)		(574	)
Non-current portion	$	—		$	—

Insurance Financing

In October 2025,  the Company entered into a financing arrangement with a lender to finance a portion of the annual premium of an insurance policy in the amount of $0.7 million. Interest on the financing agreement was 7.940% per annum. The October 2025 financing agreement is to be paid in 10 monthly installments, with the final installment set for August 2026.

In October 2024, the Company entered into a financing arrangement with a lender to finance a portion of the annual premium of an insurance policy in the amount of $0.7 million. Interest on the financing agreement was 8.440% per annum. The October 2024 financing agreement was to be paid in 10 monthly installments, but was paid in full in June 2025.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2025	Mar. 24, 2026	Jun. 30, 2025
Document Information [Line Items]
Entity Central Index Key	0001831868
Entity Registrant Name	SeaStar Medical Holding Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2025
Document Transition Report	false
Entity File Number	001-39927
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-3681132
Entity Address, Address Line One	3513 Brighton Blvd., Suite 410
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80216
City Area Code	844
Local Phone Number	427-8100
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 7,300,000
Entity Common Stock, Shares Outstanding		3,993,719
Auditor Firm ID	100
Auditor Name	WithumSmith+Brown, PC
Auditor Location	East Brunswick, New Jersey
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Common Stock for $2,875 per share
Trading Symbol	ICUCW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	ICU
Security Exchange Name	NASDAQ

Note 8 - Warrants - Schedule of Inputs for Warrant Tranches (Details) - $ / shares	Dec. 31, 2025	Feb. 28, 2025	Feb. 03, 2025	Dec. 31, 2024	Jan. 31, 2024
Private Placement Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	22,952			22,952
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2,875			$ 2,875
Weighted-average time to maturity (Year)	1 year 9 months 25 days			2 years 9 months 25 days
PIPE Investor Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	2,000			2,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2,875			$ 2,875
Weighted-average time to maturity (Year)	1 year 9 months 25 days			2 years 9 months 25 days
August 2025 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	530,779
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 7.85
Weighted-average time to maturity (Year)	4 years 7 months 9 days
July 2024 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	101,422			101,422
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 107.23			$ 107.2
Weighted-average time to maturity (Year)	3 years 6 months 10 days			4 years 6 months 10 days
July 2025 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	560,944
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 6.59
Weighted-average time to maturity (Year)	4 years 7 months 9 days
January 2024 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	67,213	65,046		67,213
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 23.82		$ 207.6	$ 208.27	$ 17
Weighted-average time to maturity (Year)	3 years 5 months 8 days			3 years 3 days
June 2025 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	994,616
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 6.57
Weighted-average time to maturity (Year)	3 years 1 month 24 days
Public Stockholders' Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	42,200			42,200
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2,875			$ 2,875
Weighted-average time to maturity (Year)	2 years 3 months 29 days			2 years 9 months 25 days
February 2025 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	377,648
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 17.34
Weighted-average time to maturity (Year)	4 years 2 months 26 days
Legacy Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	150			196
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2,500			$ 2,500
Weighted-average time to maturity (Year)	1 year 2 months 1 day			1 year 4 months 17 days

Note 9 - Common Stock and Preferred Stock

12 Months Ended

Dec. 31, 2025

Common and Preferred Stock [Text Block]

Note 9. Common Stock and Preferred Stock

As of December 31, 2025, the Company is authorized to issue 460,000,000 shares, consisting of (a) 450,000,000 shares of common stock and (b) 10,000,000 shares of preferred stock (the “Preferred Stock”). On December 18, 2025, the Company’s shareholders voted at a Special Meeting to reduce the authorized shares of common stock to 425,000,000. The change became effective on January 5, 2026.

Common stock

The charter of the Company (the “Charter”) provides the following with respect to the rights, powers, preferences, and privileges of the common stock.

Voting power

Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of the Company’s directors and all other matters requiring stockholder action. Holders of common stock are entitled to one voter per share on matters to be voted on by stockholders. The Charter does not provide for cumulative voting rights.

Dividends

Subject to the rights, if any, of the holders of any outstanding shares of preferred stock, under the Charter, holders of common stock will be entitled to receive such dividends, if any, as may be declared from time to time by the Board of Directors in its discretion out of funds legally available therefor.

Liquidation, dissolution and winding-up

In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available for distribution to stockholders after the rights of the holders of the Preferred Stock have been satisfied and after payment or provision for payment of the Company’s debts.

Preemptive or other rights

There are no preemptive rights or sinking fund provisions applicable to the shares of the Company’s common stock.

Preferred stock

The Charter provides that shares of preferred stock may be issued from time to time in one or more series. The Board of Directors is authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional, or other special rights and any qualifications, limitations, and restrictions thereof, applicable to the shares of each series. The Company has no preferred stock outstanding at December 31, 2025 or 2024.

Note 9 - Common Stock and Preferred Stock (Details Textual) - shares	Jan. 05, 2026	Dec. 31, 2025	Dec. 31, 2024
Total Shares Authorized (in shares)		460,000,000
Common Stock, Shares Authorized (in shares)		450,000,000	500,000,000
Preferred Stock, Shares Authorized (in shares)		10,000,000	10,000,000
Preferred Stock, Shares Outstanding (in shares)		0	0
Subsequent Event [Member]
Common Stock, Shares Authorized (in shares)	425,000,000

Note 13 - Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Text Block]

Note 13. Income Taxes

The Company recorded approximately $3 thousand and $3 of current income tax expense for the years ended December 31, 2025 and 2024, respectively. The Company paid approximately $2 thousand to California, and less than $1 thousand each to North Carolina and New Jersey during the year ended December 31, 2025, comprised of statutory minimum taxes.

The table before provides the updated requirements of ASU 2023-09 for 2025 (see Note 2. Summary of Significant Accounting Policies – Recent accounting pronouncements for additional details on the adoption of ASU 2023-09.

The effective income tax rate of the Company’s provision for income taxes for the year ended December 31, 2025, differed from the federal statutory rate as follows (in thousands and percentages):

	*Year Ended December 31, 2025*
	*Amount*			*Percent*
Federal tax at statutory rate	$	(2,551	)	$	21.00	%
State Tax net of federal benefits		4			-0.03	%
R&D tax credit		(275	)		2.27	%
Nontaxable or nondeductible items		(3	)		0.01	%
Change in Valuation Allowance		2,740			-22.44	%
Other Adjustments		88			-0.85	%
Tax Expense	$	3		$	-0.03	%

As previously disclosed for the years ended December 31, 2024, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income rate as follows:

	*Year Ended December 31, 2024*
	*Amount*			*Percentages*
Federal tax at statutory rate	$	(5,214	)	$	21.00	%
State income tax		776			-3.12	%
R&D tax credit		(197	)		0.79	%
Stock compensation expense		18			-0.07	%
Unrealized gains and losses, net, for liability classified warrants		146			-0.59	%
Unrealized gains and losses, net, for convertible debt		1,291			-5.20	%
Adjustment to prior period federal deferred tax assets		95			-0.38	%
Non-deductible expenses		6			-0.03	%
Other		172			-0.68	%
Change in valuation allowance		2,910			-11.72	%
Total effective income tax rate	$	3		$	0.00	%

Significant components of deferred tax assets for federal and state income taxes were as follows:

	*December 31,*			*December 31,*
	*2025*			*2024*
Deferred tax assets:
Net operating losses	$	26,779		$	23,936
Finance charges and origination fees		—			133
Accrued compensation		141			314
Stock-based compensation		87			47
Section 174 research and development capitalization		2,099			2,771
Section 59(e) research and development capitalization		1,292			—
Capitalized start-up fees		197			209
Tax credits		1,394			1,103
Total deferred tax assets		31,989			28,513
Valuation allowance		(31,989	)		(28,513	)
Net deferred tax assets	$	—		$	—

In accordance with U.S. GAAP, a valuation allowance should be provided if it is more likely than not that some or all of the Company’s deferred tax assets will not be realized. The Company’s ability to realize the benefit of its deferred tax assets will depend on the generation of future taxable income. Due to the uncertainty of future profitable operations and taxable income, the Company has recorded a full valuation allowance against its net deferred tax assets. For the years ended December 31, 2025 and 2024, the net increase in the valuation allowance was approximately $3.5 million and $2.8 million, respectively.

As of December 31, 2025 and 2024, the Company had federal net operating loss carryforwards of approximately $117.9 million and $108.4 million, respectively, of which approximately $65.0 million of federal net operating loss carryforwards post 2017 will be carried forward indefinitely. The remaining $52.8 million of federal net operating loss carryforwards begin expiring in 2027. The Company has also generated approximately $11.4 million of net operating loss carryforwards in California carryforward for 20 years, first expiring in 2039, $4.0 million of Florida net operating losses that carryforward indefinitely; $7.1 million of Illinois net operating loss carryforwards that carryforward for 20 years, first expiring in 2044 and $1.7 million of net operating loss carryforwards in Virginia that carryforward indefinitely. The Company has not used any net operating loss carryforwards to date.

The Company has not claimed any federal or state Research Credit carryforwards pre-2022. The Company believes that the Company has qualified research activities and qualified research expenses, but missed claiming the R&D credits in prior years. The tax provision reports no pre-2022 R&D credit carryforwards, consistent with the tax return filings through 2021. The Company will record R&D credit deferred tax assets (and the related valuation allowance) if/when the Company amends prior year tax filings to claim R&D credits.

The Company had federal energy credit carryforwards of approximately $0.6 million as of December 31, 2025 and 2024, which will expire starting in 2027 if not utilized. The Company has federal research and development credit carryforwards of approximately $0.7 million and $0.5 million as of December 31, 2025 and 2024, respectively, which will expire starting in 2042 if not utilized.

Pursuant to Internal Revenue Code (“IRC”) Sections 382 and 383, the Company’s ability to use net operating losses (“NOL”) and research tax credit carryforwards to offset future taxable income may be limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of NOL and research tax credit carryforwards available to offset future taxable income and income tax liabilities in future years may be significantly restricted or eliminated. Further, deferred tax assets associated with such NOLs, and research tax credits could be significantly reduced upon realization of an ownership change within the meaning of IRC Section 382.

The Company files U.S. federal and state tax returns with varying statutes of limitations. Due to net operating loss and credit carryforwards, the 2019 to 2024 tax years remain subject to examination by the U.S. federal and some state authorities. The actual amount of any taxes due could vary significantly depending on the ultimate timing and nature of any settlement.

Uncertain Tax Benefits

The Company uses the “more likely than not” criterion for recognizing the income tax benefit of uncertain income tax positions and establishing measurement criteria for income tax benefits. As of December 31, 2025, the Company has approximately $1.1 million of uncertain tax benefits, all of which are accounted for as contra deferred tax assets. The following schedule provides the roll forward of the Company’s uncertain tax positions during the year ended December 31, 2025:

	*Uncertain Tax Position*
Balance as of December 31, 2024	$	944
Increase in prior year		—
Increase in current year		127
Balance as of December 31, 2025	$	1,071

The Company has no accrued interest related to the uncertain tax benefits. The Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months as of December 31, 2025.

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

Note 4 - Trade Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Accounts receivable, gross, balance	$ 112
Allowance for credit loss, balance	0
Accounts receivable, net, balance	112
Changes in accounts receivable, gross	128
Changes in accounts receivable, allowance	(3)
Changes in accounts receivable	125	$ 112
Accounts receivable, gross, balance	240	112
Allowance for credit loss, balance	(3)	0
Accounts receivable, net, balance	$ 237	$ 112

Note 6 - Notes Payable - Summary of Notes Payable (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Note Payable	$ 525	$ 574
Less current portion	(525)	(574)
Non-current portion	$ 0	$ 0

Note 10 - Stock-Based Compensation Awards

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement [Text Block]

Note 10. Stock-Based Compensation Awards

The following table sets forth the total stock-based compensation cost included in the Company’s consolidated statements of operations for the years ended December 31, 2025 and 2024:

	Year Ended December 31,
($ in thousands)	2025		2024
Research and development	$	91	$	157
General and administrative		533		730
Total stock-based compensation	$	624	$	887

Equity incentive plan - summary

2022 Omnibus Incentive Plan

The Company’s Board of Directors adopted, and the shareholders approved the 2022 Omnibus Incentive Plan to provide long-term incentive for its employees and non-employee service providers. The vesting of stock options is stated in each individual grant agreement, which is generally either one or four years. Options granted expire 10 years after the date of grant.

2019 Stock Incentive Plan

The Company’s Board of Directors adopted the 2019 Stock Incentive Plan on February 25, 2019, to provide long-term incentive for its employees and non-employee service providers. The Stock Incentive Plan was terminated on October 28, 2022, and no further awards were granted under such plan.

Stock Options

Option activity for the year ended December 31, 2025, is as follows:

2022 Omnibus Incentive Plan - Options

	Options			Weighted-Average Exercise Price		Total Intrinsic Value		Weighted-Average Remaining Contractual Life (Years)
Outstanding at December 31, 2024	1,315			$	460.00	$	—	8.2
Exercised		—
Issued		—
Forfeited / cancelled		(192	)
Outstanding at December 31, 2025		1,123		$	460.00	$	—		7.2
Vested and exercisable at December 31, 2025		1,123		$	460.00	$	—		7.2

2019 Stock Incentive Plan - Options

	Options			Weighted-Average Exercise Price		Total Intrinsic Value		Weighted-Average Remaining Contractual Life (Years)
Outstanding at December 31, 2024	885			$	443.00	$ —		5.5
Exercised		—
Issued		—
Forfeited / cancelled		(196	)
Outstanding at December 31, 2025		689		$	533	$	—		4.4
Vested and exercisable at December 31, 2025		689		$	533	$	—		4.4

Restricted Stock Units

A summary of the Company’s restricted stock unit (“RSU”) activity for the year ended December 31, 2025, is as follows:

2022 Omnibus Incentive Plan - RSUs

	Number of RSU			Weighted-Average Grant Date Fair Value (per share)
Outstanding at December 31, 2024		21,950		$	50.90
Granted		13,000
Vested		(8,080	)
Forfeited / cancelled		(1,000	)
Outstanding at December 31, 2025		25,870		$	30.50

2019 Stock Incentive Plan - RSUs

	Number of RSU			Weighted-Average Grant Date Fair Value (per share)
Outstanding at December 31, 2024		75		$	2,000.00
Granted		—
Vested		(75	)
Forfeited / cancelled		—
Outstanding at December 31, 2025		—		$	—

Note 6 - Notes Payable (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Debt [Table Text Block]

($ in thousands)	*December 31, 2025*			*December 31, 2024*
Insurance financing	$	525		$	574
Less current portion		(525	)		(574	)
Non-current portion	$	—		$	—

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2025

Significant Accounting Policies [Text Block]

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of revenues and expenses during the period. Significant estimates for the year ended December 31, 2025, include the (i) valuation of the liability classified warrants, (ii) unbilled clinical trial costs, and (iii) stock-based compensation expense. Although actual results could differ from those estimates, such estimates are developed based on the best information available to management and management’s best judgments at the time.

Cash and cash equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company did not have any cash equivalents as of December 31, 2025 and 2024.

Concentrations of credit risk

Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

Accounts Receivable

The Company recognizes accounts receivables from sales to customers at the time revenue is recognized and a customer invoice is created. The need for a credit loss allowance is evaluated each reporting period based on the Company’s assessment of the credit worthiness of its customers or any other potential circumstances that could result in a credit loss. The Company initially estimates credit losses based on a portfolio-wide method using an aging schedule at the end of each reporting period. Any customer specific collections subsequent to the reporting period are then adjusted accordingly. As of December 31, 2025 and 2024, the Company had a current expected credit loss reserve of $3 thousand and $0, respectively.

Income taxes

The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the consolidated financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to apply to taxable income in the periods in which such differences are expected to reverse. A valuation allowance is provided when the realization of net deferred tax assets is not deemed more likely than not.

The Company complies with the provisions of Accounting Standards Codification (“ASC”) 740, Income Taxes, which provides a comprehensive model for the recognition, measurement, and disclosure in consolidated financial statements of uncertain income tax positions that a company has taken or expects to take on a tax return. Under this guidance, a company can recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position; otherwise, no benefit can be recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. Additionally, the Company accrues interest and related penalties, if applicable, on all tax exposures for which reserves have been established consistent with jurisdictional tax laws. Interest and penalties are classified as income tax expense in the consolidated financial statements.

Use of Derivative Instruments

The Company’s derivative instruments historically have consisted of financial instruments that arose as part of the Company’s ongoing efforts to raise capital to fund the Company’s operations. It is likely that ongoing efforts to raise capital in the future will result in additional derivative instruments to be issued as part of those efforts. The Company has not nor does it intend to utilize derivative instruments for risk management (i.e. hedging) or investing activities.

These derivative instruments have taken the form of warrants, convertible debt, and other financing arrangements such as a prepaid forward purchase option. The classification of these financial instruments as either a component of liabilities or equity is specific to the terms within each financial instrument agreement. and the application of U.S. GAAP. For those that are liability classified, the Company recognized changes in the fair value of each financial instruments as a “non-operating income / (expense)” component of the consolidated statement of operations and an adjustment to operating cash flows within the consolidated statement of cash flows each reporting period.

The issuance of each derivative instrument is reported as a proceed in the financing section to the consolidated statement of cash flows, while the ultimate settlement of each derivative instrument could be reported either as an adjustment to operating cash flows, paydown within financing cash flows, or a non-cash transaction depending on the settlement.

Fair value option of accounting

Generally, when financial instruments are first acquired that are not required to be recorded at fair value per U.S. GAAP, ASC 825, Financial Instruments allows an entity to elect the fair value option (“FVO”). The FVO may be elected on an instrument-by-instrument basis only at the time of acquisition and once elected is irrevocable. The FVO allows an entity to account for the entire financial instrument at fair value with subsequent changes in fair value recognized in earnings through the consolidated statements of operations at each reporting date. A financial instrument is generally eligible for the FVO if, amongst other factors, no part of the financial instrument is classified in stockholders’ equity.

Based on the eligibility assessment discussed above, the Company historically concluded that its previously held convertible notes were eligible for the FVO and accordingly elected the FVO for those debt instruments. This election was made because of operational efficiencies in valuing and reporting for these debt instruments at fair value in their entirety at each reporting date. The convertible notes contained certain embedded derivatives that otherwise would require bifurcation and separate accounting at fair value.

The convertible notes, inclusive of their respective accrued interest at the stated interest rates (collectively referred to as the “FVO debt instruments”) were initially recorded at fair value as liabilities on the consolidated balance sheets and subsequently re-measured at fair value at the end of each reporting period presented within the consolidated financial statements until they were settled in 2024. The changes in fair value of the FVO debt instruments are recorded in changes in fair value of convertible notes, included as a component of other income (expense), net, in the consolidated statements of operations.

The Company did not have any convertible notes outstanding during the year ended December 31, 2025.

Fair value of financial instruments

The following provides a summary of those assets or liabilities for which the Company is required to measure at fair value either on a recurring basis, the valuation techniques and summary of inputs used to arrive at the measure of fair value. Changes in fair value of these assets or liabilities are recognized as a component of net income in the consolidated statements of operations. Changes in fair value of these assets or liabilities are considered unrealized gains or losses and therefore are classified as non-cash adjustments to reconcile net income to operating cash flows. Significant increases (decreases) in unobservable inputs used in fair value measurements could, in isolation, potentially result in a significantly lower or higher valuation for those assets or liabilities requiring recurring fair value measurements at each reporting date.

Liability Classified Warrants. The Company has entered into or assumed various financial instruments, in the form of warrant agreements, that require classification as liabilities. This classification requires that the Company measure the warrants at each fair value at the end of each quarterly and annual reporting period.

The Company uses a Black-Scholes option pricing model to fair value the warrants, using standard option pricing inputs such as the strike price of each warrant tranche, estimated volatility, time to maturity, and the risk-free interest rate. The risk-free interest rate is the U.S. Treasury rate at the date of issuance, and the time to maturity is based on the contractual life at the date of issuance, which is five years. The change in fair value of the liability classified warrants each reporting period is recorded to the change in fair value of warrants liability in the consolidated statements of operations.

Operating Current Assets and Current Liabilities. The estimated fair value of cash, accounts receivables, prepaid expenses, accounts payable and accrued expenses approximate their fair value because of the short-term nature of these instruments.

Classification of Derivative Gains and Losses on the Consolidated Statement of Cash Flows. Changes in fair value related to the Company’s derivative financial instruments consisting of (i) liability classified warrants and (ii) convertible notes are classified in operating cash flows as adjustments to net income. During the year ended December 31, 2025, the only activity related to liability classified warrants, as the Company fully settled all outstanding convertible notes during the year ended December 31, 2024.

Revenue Recognition

Overall

Under ASC Topic 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the Company evaluates the following criteria: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied.

At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct combined performance obligation is identified. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. The Company constrains revenue by giving consideration to factors that could otherwise lead to a probable reversal of revenue. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant.

The Company records any payments received from customers prior to the Company fulfilling its performance obligation(s) as contract obligations. Amounts expected to be recognized as revenue within the one year following the consolidated balance sheet date are classified as current contract obligations. Amounts not expected to be recognized as revenue within the one year following the consolidated balance sheet date are classified as contract obligations, net of current portion. See Note 3 – Revenues and Contract Obligations for further details.

Product Sales Revenue

The Company has sold and intends to continue to sell its products either through a combination of distributor(s) and/or directly to end-user qualified customers through the Company’s own internal commercial/sales resources. The acting distributor during the year ended December 31, 2024 subsequently resold and was to continue to resell the products to present and future customers, until such time the Company terminated its agreement with the distributor (see Note 3).

•

Timing of Revenue Recognition – During the brief history (commenced July 2024) of selling QUELIMMUNE, revenue has been recognized based on a freight-on-board destination (“FOB Destination”) requirement.

•

Chargebacks, Government Rebates and Discounts – During the brief history of selling pediatric SCDs commercially, the Company has not agreed to chargebacks, government rebates or discounts.

•

Returns – Returns are specific to each order, but generally the Company allows for returns of any damaged or non-conforming product within 30 days of receipt of product. Given the (i) overall rate of product shipped that is defective/damaged, (ii) overall volume of sales to individual end-user customers, (iii) expected supply in the customer channel, and (iv) expected usage by customers, the Company does not anticipate that there will be significant risk of product returns overall.

•

Variable Consideration – the Company does not currently estimate a constraint on revenue recognized on product sales.

•

Transaction Price – based on the above, as currently constructed, the Company’s transaction price is fixed, based on the agreed-upon price per each purchase order submitted by each customer. Milestone or up-front payments unique to the former distributor, disclosed in Note 3, were not recognized as revenue, but were returned as a result of a settlement to cease the relationship with the distributor.

•

Allocation of Consideration – each sale of a pediatric SCD is independent of any and all other sales. The entire transaction price for each pediatric SCD is allocated to the sale of that pediatric SCD.

The Company will continue to monitor all of the above as the Company continues to commercialize and increase its customer base, which could result with each distributor or end-user customer agreement resulting in its own unique terms and conditions, that will potentially impact the timing and amount of revenue recognition pursuant to U.S. GAAP.

Cost of Goods Sold

Prior to July 2024, the Company manufactured/assembled QUELIMMUNE and adult SCDs only for research oriented and/or clinical trial related activities. Inventory purchased prior to July 2024 was expensed as a period expense at the time of purchase as a research and development expense. Accordingly, all QUELIMMUNE units sold prior to the three months ended June 30, 2025, had no recognized inventory value. During the year ended December 31, 2025, the Company recognized approximately $53 thousand for cost of goods sold.

The Company purchases supplies for the production of QUELIMMUNE and adult SCDs, some of which is used in the production of both. The Company's policy for the accounting for these three categories of inventory as follows:

	•	QUELIMUNE Specific Inventory – comprises raw materials used solely for the assembly of QUELIMMUNE inventory. It will be recognized to inventory as either raw materials, work-in-process, or finished goods depending on the stage of assembly. It will be charged to cost of goods sold upon shipment to a customer.

	•	Commingled Inventory – comprises raw materials that are used both for the assembly of QUELIMMUNE or adult SCDs. If used in the assembly of QUELIMMUNE, it will continue to be included in inventory as either work-in-process or finished goods depending on the stage of assembly and charged to cost of goods sold upon shipment to a customer.

	•	Adult SCD Specific Inventory – comprises raw materials used solely for the assembly of adult SCDs primarily to fulfill the demands of the NEUTRALIZE-AKI study. These supplies will be charged to research and development expense upon acquisition, until such time, that it is probable that these supplies could be assembled into adult SCD kits to be sold commercially.

Stock-based compensation

In accordance with ASC Topic 718, Compensation – Stock Compensation, the Company recognizes compensation expense for all stock-based awards issued to employees based on the estimated grant-date fair value, which is recognized as expense on a graded vesting approach over the requisite service period. The Company has elected to recognize forfeitures as they occur. The fair value of stock options is determined using the Black-Scholes option-pricing model. The determination of fair value for stock options on the date of grant using an option-pricing model requires management to make certain assumptions including implied volatility, expected term, risk-free interest rate and expected dividends ($nil) in addition to the Company’s common stock valuation. The determination of fair value of restricted stock units is valued based on the value of the Company’s common stock on the grant date.

Research and development expenses

Expenditures made for research and development are charged to expense as incurred. External costs consist primarily of payments for laboratory supplies purchased in connection with the Company’s discovery and preclinical activities, and process development and clinical development activities. Internal costs consist primarily of employee-related costs, consultants fees and costs related to compliance with regulatory requirements.

The Company records expenses related to external research and development services based on services received and efforts expended pursuant to invoices and contracts with consultants that supply, conduct, and manage preclinical studies and clinical trials on its behalf.

Funded Research & Development Expense

During the year ended December 31, 2025, the Company entered into an agreement to provide contract research services to an outside party, which involves a study of the Company's selective cytopheretic device relating to patients with severe, chronic heart failure. The Company is able to bill the outside party for a certain portion of the costs incurred to provide these services. The Company will own and is able to benefit from the knowledge gained from the results of this study. Accordingly, the Company will account for any funds paid by the outside party to the Company as a reimbursed expense, in accordance with ASC 730-20 as a funded research and development arrangement. Accordingly, any amounts incurred and billed will offset the Company's operating expenses categorized as research and development expense on the Company’s condensed consolidated statement of operations for the year ended December 31, 2025. The reimbursed expenses for the year ended December 31, 2025, totaled approximately $0.4 million. No funded research and development agreement existed in 2024.

Emerging growth company status

The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (1) no longer an emerging growth company or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.

Net loss per share attributable to common stockholders

The Company’s basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period. The dilutive effect of these potential common shares is reflected in diluted earnings per share by application of the treasury stock method. See Note 14 for disclosures on exclusion of certain instruments which would be anti-dilutive in circumstances where the Company is reporting a net loss for that earnings period. Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities as certain outstanding warrants are considered participating securities. The Company’s participating securities do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for the periods presented, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders for these periods. The significant increase in common stock outstanding is expected to impact the year-over-year comparability of the Company’s net loss per share calculations.

Recently adopted accounting standards

Accounting Standards Update 2023-09 — In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740) Improvements to Income Tax Disclosures. ASU 2023-09 enhances the transparency and decision usefulness of income tax disclosures. The amendments in this update are effective for public business entities for annual periods beginning after December 15, 2024. Early adoption was permitted, but the Company elected not to early adopt and adopted for the year ended December 31, 2025. ASU 2023-09 requires the Company to consistently categorize and provide greater disaggregation of information in the rate reconciliation it must further disaggregate income taxes paid. However, as the Company is currently generating net operating losses, pays no federal and limited state taxes and does not operate in foreign jurisdictions, this does not have a significant impact to the Company's income tax disclosures (see Note 13).

Recently issued accounting standards not yet adopted

Accounting Standards Update 2024-03 — In November 2024, the FASB issued ASU 2024-03 - Income Statement - Reporting Comprehensive Income – Expense Disaggregation (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 requires the disclosure of additional information related to certain costs and expenses, including amounts of inventory purchases, employee compensation, and depreciation and amortization included in each income statement line item. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this guidance on its consolidated financial statements and disclosures.

Note 14 - Net Loss Per Share - Calculation of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Net loss	$ (12,150)	$ (24,830)
Weighted-average shares outstanding - basic and diluted (in shares)	2,073,087	374,356
Basic and diluted net loss per share (in dollars per share)	$ (5.86)	$ (66.33)

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Note 10 - Stock-based Compensation Awards - Summary of Stock-based Compensation Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Stock-based compensation	$ 624	$ 887
Research and Development Expense [Member]
Stock-based compensation	91	157
General and Administrative Expense [Member]
Stock-based compensation	$ 533	$ 730

Note 15 - Segment Reporting - Summary of Segment Reporting (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Revenue from Contract with Customer, Excluding Assessed Tax	$ 1,234	$ 135
Cost of Product and Service Sold	53	0
Gross profit	1,181	135
Operating expenses
Research and development	7,518	9,105
General and administrative	5,838	8,872
Total operating expenses	13,356	17,977
Loss from operations	$ (12,175)	$ (17,842)

+ References + Details

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

The net result for the period of deducting operating expenses from operating revenues.

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

Note 10 - Stock-based Compensation Awards - 2022 Omnibus Incentive Plan, RSUs (Details) - The 2022 Omnibus Equity Incentive Plan [Member] - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Outstanding, number (in shares) \| shares	21,950
Outstanding, weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 50.9
Granted, number (in shares) \| shares	13,000
Granted, weighted-average grant date fair value (in dollars per share) \| $ / shares
Vested, number (in shares) \| shares	(8,080)
Vested, weighted-average grant date fair value (in dollars per share) \| $ / shares
Forfeited / cancelled, number (in shares) \| shares	(1,000)
Forfeited / cancelled, weighted-average grant date fair value (in dollars per share) \| $ / shares
Outstanding, number (in shares) \| shares	25,870
Outstanding, weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 30.5

Note 10 - Stock-based Compensation Awards - 2019 Stock Incentive Plan, RSUs (Details) - The 2019 Omnibus Incentive Plan [Member] - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2025 $ / shares shares
Outstanding, number (in shares) \| shares	75
Outstanding, weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 2,000
Granted, number (in shares) \| shares	0
Granted, weighted-average grant date fair value (in dollars per share) \| $ / shares
Vested, number (in shares) \| shares	(75)
Vested, weighted-average grant date fair value (in dollars per share) \| $ / shares
Forfeited / cancelled, number (in shares) \| shares	0
Forfeited / cancelled, weighted-average grant date fair value (in dollars per share) \| $ / shares
Outstanding, number (in shares) \| shares	0
Outstanding, weighted-average grant date fair value (in dollars per share) \| $ / shares	$ 0

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets
Cash	$ 11,980	$ 1,819
Accounts receivable, net of allowance for credit losses of $3 and $0, respectively	237	112
Inventory	66	0
Prepaid expenses	1,297	1,835
Total current assets	13,580	3,766
Other assets	578	892
Total assets	14,158	4,658
Current liabilities
Accounts payable	948	3,046
Accrued expenses	2,268	3,188
Notes payable, net of deferred financing costs	525	574
Liability classified warrants	1	33
Total current liabilities	3,742	6,841
Total liabilities	3,742	6,841
Commitments and contingencies (Note 11)
Stockholders’ equity/(deficit)
Preferred stock - $0.0001 par value, 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; no shares issued and outstanding at December 31, 2025 and December 31, 2024	0	0
Common stock - $0.0001 par value per share; 450,000,000 and 500,000,000 shares authorized at December 31, 2025 and December 31, 2024, respectively; 3,844,613 and 650,639 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively	4	2
Additional paid-in capital	162,126	137,379
Accumulated deficit	(151,714)	(139,564)
Total stockholders’ equity/(deficit)	10,416	(2,183)
Total liabilities and stockholders’ equity/(deficit)	$ 14,158	$ 4,658

Note 12 - Fair Value Measurements - Summary of Changes in Fair Value Liabilities (Details) - Forward Purchase Agreement Derivative Liability [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)
Balance	$ 33
Additions	0
Cash paid to settle	0
Shares issued upon conversion or exercise	0
Changes in fair value	(32)
Balance	$ 1

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Net revenue	$ 1,234	$ 135
Cost of goods sold	53	0
Gross profit	1,181	135
Operating expenses
Research and development	7,518	9,105
General and administrative	5,838	8,872
Total operating expenses	13,356	17,977
Loss from operations	(12,175)	(17,842)
Other income (expense)
Interest income	325	101
Interest expense	(31)	(244)
Other financing costs	(298)	0
Change in fair value of convertible notes	0	(6,145)
Change in fair value of warrants liability	32	(697)
Total other income (expense), net	28	(6,985)
Loss before provision for income taxes	(12,147)	(24,827)
Provision for income taxes	3	3
Net loss	$ (12,150)	$ (24,830)
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (5.86)	$ (66.33)
Weighted-average shares outstanding, basic and diluted (in shares)	2,073,087	374,356

Note 5 - Accrued Expenses

12 Months Ended

Dec. 31, 2025

Summary of Accrued Expenses [Text Block]

Note 5. Accrued Expenses

Accrued expenses consisted of the following amounts as of December 31, 2025 and 2024:

($ in thousands)	*December 31, 2025*		*December 31, 2024*
Accrued research and development	$	1,525	$	1,023
Accrued bonus		150		1,391
Accrued director compensation		70		391
Other		523		383
Total accrued expenses	$	2,268	$	3,188

Note 3 - Revenues and Contract Obligations

12 Months Ended

Dec. 31, 2025

Revenue from Contract with Customer [Text Block]

Note 3. Revenues and Contract Obligations

In December 2022, the Company entered into a License and Distribution Agreement (the “Distribution Agreement”) with Nuwellis, Inc. (“Nuwellis”) granting exclusive distribution rights of the Company’s pediatric SCD within the United States of America. Under the terms of the Distribution Agreement, Nuwellis would pay the Company consideration comprising both (i) a per unit sales price for each unit shipped and (ii) a royalty for all units sold to customers.

In addition, Nuwellis also agreed to pay (i) a $100 thousand upfront payment at contract inception (the “Up-front Payment”), and (ii) two contingent milestones payments consisting of (a) $450 thousand payment upon meeting the regulatory milestone of receiving HDE approval from the FDA (the “Regulatory Milestone Payment”), and (b) $300 thousand payment upon meeting a sales-based milestone (the “Sales Based Milestone Payment”).

The Company had the following performance obligations within the Distribution Agreement: (i) a material right to Nuwellis consisting of an exclusive option for Nuwellis to purchase additional pediatric SCDs during the term of the Distribution Agreement for a discounted price, (ii) to provide training to Nuwellis personnel and medical professionals at end-user customers of Nuwellis and (iii) upon each receipt of a valid Nuwellis purchase order, delivery of pediatric SCDs. The transaction price for the Nuwellis material right and training is comprised of the Upfront Payment, the Regulatory Milestone Payment and the Sales Based Milestone Payment. The transaction price for each pediatric SCD device sold was the actual price for each device and the estimated royalties to be received.

Prior to the Company’s termination of the Distribution Agreement discussed below, the Company received full consideration for the Up-front Payment and the Regulatory Milestone Payment for a total of $550 thousand, which had been recorded as contract liabilities and was to be recognized over the remaining term of the Distribution Agreement. However, the Company and Nuwellis entered into a confidential settlement agreement on October 20, 2024 (the “Settlement Agreement”), in connection with the Company’s termination of the Distribution Agreement on August 18, 2024. Under the Settlement Agreement the Company agreed to refund Nuwellis the entire $550 thousand comprising of the Upfront Payment and Regulatory Milestone plus an additional $350 thousand for a total of $900 thousand, of which the $350 thousand was charged to general and administrative expense. The amounts were paid to Nuwellis in three installments during the quarter ended December 31, 2024.

As a result, the Company (i) was precluded from recognizing revenue of approximately $0.1 million for product shipments to Nuwellis during the year ended December 31, 2024, (ii) was precluded from recognizing any revenues related to contract liabilities arising the Upfront Payment and Regulatory Milestone through December 31, 2024, (see below), and (iii) does not anticipate there will be any future shipments of pediatric SCDs to Nuwellis going forward. Due to the termination of the Distribution Agreement and related Settlement Agreement, the Company did not recognize any revenue from the Up-Front Payment or the Regulatory Milestone Payment as it refunded the payments to Nuwellis as part of the Settlement Agreement.

Since the termination of the Distribution Agreement, the Company developed its own commercial operations and sold approximately $1.2 million and $0.1 million to end-user customers during the years ended December 31, 2025 and 2024, respectively.

The following table summarizes the changes in the Company’s contract liability balance for the years ended December 31, 2025 and 2024:

	*Year Ended December 31,*
($ in thousands)	*2025*		*2024*
Contract liabilities, beginning of period	$	—	$	100
Consideration received		—		450
Consideration refunded		—		(550	)
Contract liabilities, end of period	$	—	$	—

The Company had no contract assets at the beginning or end of the fiscal years ended December 31, 2025 and 2024. The accounting policies used to measure the profit and loss of the segment are the same as those described in the summary of significant accounting policies.

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

Note 12 - Fair Value Measurements

12 Months Ended

Dec. 31, 2025

Fair Value Disclosures [Text Block]

Note 12. Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Inputs used to measure fair value are classified into the following hierarchy:

Level 1 – quoted prices in active markets for identical assets and liabilities.

Level 2 – other significant observable inputs (including quoted prices for similar assets and liabilities, quoted prices for identical assets in inactive markets, interest rate, credit risk, etc.).

Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of assets and liabilities).

The fair value of the forward option on prepaid forward contracts, convertible notes, and the warrants liability is classified as Level 3 in the fair value hierarchy.

Fair Value Measurement Hierarchy

The following table presents the Company’s financial assets and/or liabilities that were accounted for at fair value on a recurring basis as of December 31, 2025 and 2024, by level withing the fair value hierarchy. There were no non-recurring fair value measurements, as the Company does not have any long-lived assets, including fixed assets, intangible assets or goodwill which can require non-recurring measurements for impairment.

	Fair Value Measurements at December 31, 2025
	(Level 1)		(Level 2)		(Level 3)		Total
*Liabilities:*
Liability classified warrants	$	—	$	—	$	1	$	1
	$	—	$	—	$	1	$	1

	Fair Value Measurements at December 31, 2024
	(Level 1)		(Level 2)		(Level 3)		Total
*Liabilities:*
Liability classified warrants	$	—	$	—	$	33	$	33
Total	$	—	$	—	$	33	$	33

Summary of Level 3 Input Changes

The following table presents the changes in the liability classified warrants for the years ended December 31, 2025 (in thousands):

Level 3 Roll Forward	Liability Classified Warrants
Balance December 31, 2024	$	33
Additions		—
Cash paid to settle		—
Shares issued upon conversion or exercise		—
Changes in fair value		(32	)
Balance December 31, 2025	$	1

Level 3 Inputs

For assets or liabilities for which the Company is required to remeasure the fair value on a recurring basis at each reporting date, generally the Company is required to disclose certain quantitative data related to the inputs used at the most recent reporting period date. However, for those assets or liabilities for which the Company has elected to take the fair value option in accordance with ASC 825, Financial Instruments, then such quantitative disclosures are not required. As of December 31, 2025, there were no assets or liabilities for which the Company elected to take the fair value option.

Liability Classified Warrants

Significant assumptions used in valuing warrants which require liability classification were as follows as of December 31, 2025 and 2024:

	*December 31,*			*December 31,*
	*2025*			*2024*
Expected volatility		130.00	%		130.00	%
Remaining term		1.825			2.825
Risk-free rate		3.48	%		4.27	%
Dividend yield		0.00	%		0.00	%
Stock price	$	2.40		$	1.94
Strike price	$	2,875.00		$	287.50

The only liability classified warrants that were outstanding as of December 31, 2025 and 2024, were the Private and PIPE warrants. These warrants are valued using the same inputs into a Black-Scholes standard option pricing model and therefore, there is no range of inputs.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

Note 13 - Income Taxes - Reconciliation of Effective Income Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Federal tax at statutory rate	$ (2,551)	$ (5,214)
Federal tax at statutory rate, percent	21.00%	21.00%
State Tax net of federal benefits	$ 4	$ 776
State Tax net of federal benefits, percent	(0.03%)	(3.12%)
R&D tax credit	$ (275)	$ (197)
R&D tax credit, percent	2.27%	0.79%
Nontaxable or nondeductible items	$ (3)	$ 6
Nontaxable or nondeductible items, percent	0.01%
Change in Valuation Allowance	$ 2,740	$ 2,910
Change in Valuation Allowance, percent	(22.44%)	(11.72%)
Other Adjustments	$ 88	$ 172
Other Adjustments, percent	(0.85%)	(0.68%)
Tax Expense	$ 3	$ 3
Tax Expense, percent	(0.03%)	0.00%
Stock compensation expense		$ 18
Stock compensation expense, percent		(0.07%)
Unrealized gains and losses, net, for liability classified warrants		$ 146
Unrealized gains and losses, net, for liability classified warrants, percent		(0.59%)
Unrealized gains and losses, net, for convertible debt		$ 1,291
Unrealized gains and losses, net, for convertible debt, percent		(5.20%)
Adjustment to prior period federal deferred tax assets		$ 95
Adjustment to prior period federal deferred tax assets, percent		(0.38%)
Non-deductible expenses	$ (3)	$ 6
Non-deductible expenses, percent		(0.03%)
Other	$ 88	$ 172
Other, percent	(0.85%)	(0.68%)

Note 1 - Description of Business (Details Textual) $ / shares in Units, $ in Thousands			12 Months Ended		19 Months Ended
	Jan. 05, 2026 $ / shares	Jun. 07, 2024 $ / shares	Dec. 31, 2025 USD ($) $ / shares	Dec. 31, 2024 USD ($) $ / shares	Jan. 05, 2026 $ / shares	Oct. 28, 2022 $ / shares shares
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares		$ 0.0001	$ 0.0001	$ 0.0001		$ 0.0001
Retained Earnings (Accumulated Deficit) \| $			$ (151,714)	$ (139,564)
Cash \| $			11,980	1,819
Revenue from Contract with Customer, Excluding Assessed Tax \| $			$ 1,234	$ 135
Unadjusted Warrants [Member]
Class of Warrant or Right, Outstanding (in shares) \| shares						16,788,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares						$ 11.5
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) \| shares						0.04
Subsequent Event [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.0001				$ 0.0001
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		25
Reverse Stock Split [Member] \| Subsequent Event [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10				250

Note 12 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value Measurements at December 31, 2025
	(Level 1)		(Level 2)		(Level 3)		Total
*Liabilities:*
Liability classified warrants	$	—	$	—	$	1	$	1
	$	—	$	—	$	1	$	1

	Fair Value Measurements at December 31, 2024
	(Level 1)		(Level 2)		(Level 3)		Total
*Liabilities:*
Liability classified warrants	$	—	$	—	$	33	$	33
Total	$	—	$	—	$	33	$	33

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

Level 3 Roll Forward	Liability Classified Warrants
Balance December 31, 2024	$	33
Additions		—
Cash paid to settle		—
Shares issued upon conversion or exercise		—
Changes in fair value		(32	)
Balance December 31, 2025	$	1

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

	*December 31,*			*December 31,*
	*2025*			*2024*
Expected volatility		130.00	%		130.00	%
Remaining term		1.825			2.825
Risk-free rate		3.48	%		4.27	%
Dividend yield		0.00	%		0.00	%
Stock price	$	2.40		$	1.94
Strike price	$	2,875.00		$	287.50

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Income Tax Expense (Benefit)	$ 3	$ 3
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	3,500	2,800
Unrecognized Tax Benefits	1,071	944
Unrecognized Tax Benefits, Interest on Income Taxes Accrued	0
Energy Tax Credit Carryforwards [Member]
Tax Credit Carryforward, Amount	600
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	700	500
Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	117,900	$ 108,400
Operating Loss Carryforwards, Indefinite	65,000
Operating Loss Carryforwards, Subject To Expiration	$ 52,800
Open Tax Year	2019 2020 2021 2022 2023 2024
California Franchise Tax Board [Member]
Income Tax Paid, State and Local, after Refund Received	$ 2
California Franchise Tax Board [Member] \| State and Local Jurisdiction [Member]
Operating Loss Carryforwards	11,400
North Carolina Tax Authority [Member]
Income Tax Paid, State and Local, after Refund Received	1
Florida Tax Authority [Member] \| State and Local Jurisdiction [Member]
Operating Loss Carryforwards	4,000
Illinois Tax Authority [Member] \| State and Local Jurisdiction [Member]
Operating Loss Carryforwards	7,100
Virginia Tax Authority [Member] \| State and Local Jurisdiction [Member]
Operating Loss Carryforwards	1,700
New Jersey Division of Taxation [Member]
Income Tax Paid, State and Local, after Refund Received	$ 1

Note 1 - Description of Business

12 Months Ended

Dec. 31, 2025

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Note 1. Description of Business

Organization and description of business

SeaStar Medical Holding Corporation, a Delaware corporation, and its wholly owned subsidiary, SeaStar Medical, Inc. (the “Predecessor”), are collectively referred to as the “Company”. The Predecessor was incorporated as a Delaware corporation in June 2007, and it is headquartered in Denver, Colorado. The Company is a commercial stage business and also focused on product development. The Company is principally engaged in the research, development, and commercialization of a platform medical device technology designed to modulate inflammation in various patient populations. The initial target of this technology is for the treatment of acute kidney injuries in pediatric patients.

On October 28, 2022, LMF Merger Sub, Inc., a wholly owned subsidiary of LMF Acquisition Opportunities, Inc. (“LMF”), merged with and into the Predecessor (the “Business Combination”), with the Predecessor surviving the Business Combination as a wholly owned subsidiary of LMF. Following the consummation of the Business Combination, LMF was renamed to “SeaStar Medical Holding Corporation”.

Basis of Presentation

The Company’s consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”).

On June 7, 2024, the Company effected a 1-for-25 reverse-stock split (the “2024 Reverse Stock Split”) of its issued and outstanding shares of common stock, par value $0.0001 (the “common stock”). Following the effect of the 2024 Reverse Stock Split, each 25 shares of the Company’s common stock that were issued and outstanding automatically converted into one outstanding share of common stock.

On January 5, 2026, the Company elected a 1-for-10 reverse-stock split (the “2026 Reverse Stock Split,” together with the 2024 Reverse Stock Split, the “Reverse Stock Splits”) of its issued and outstanding shares of common stock, par value $0.0001 (the “common stock”). Following the effect of the 2026 Reverse Stock Split, each 10 shares of the Company’s common stock that were issued and outstanding automatically converted into one outstanding share of common stock.

Combined, this had the effect of a 1-for-250 reverse stock split. All stock options and warrants of the Company outstanding immediately prior to each of the Reverse Stock Splits were proportionally adjusted except for the Listed Warrants and the private placement warrants that were issued as part of the SPAC transaction that closed on October 28, 2022, which total 16,788,000 outstanding warrants in the aggregate (the “Unadjusted Warrants”). The Unadjusted Warrants each retained an $11.50 exercise price and require the exercise of 250 warrants to purchase one share of common stock. Unless otherwise indicated, all other share and per share amounts in this annual report reflect the effect of the Reverse Stock Splits. The par value of the Company’s common stock remained unchanged at $0.0001 per share and the number of authorized shares of common stock remained the same after each of the Reverse Stock Splits.

Liquidity and going concern

As of December 31, 2025, the Company has an accumulated deficit of approximately $151.7 million and cash of approximately $12.0 million. The Company does not believe that its cash on hand will be sufficient to enable it to fund its operations, including clinical trial expenses and capital expenditure requirements for at least 12 months from the issuance of these consolidated financial statements. The Company believes that these conditions raise substantial doubt about its ability to continue as a going concern.

The Company’s need for additional capital will depend in part on the scope and costs of its development activities. To date, the Company has generated approximately $1.2 million in revenue from the sales of QUELIMMUNE. Its ability to generate meaningful product revenue will depend on the successful launch of QUELIMMUNE and development and eventual commercialization of the adult SCD. Until such time, if ever, it expects to finance its operations through the sale of equity or debt securities, borrowing under credit facilities, or through potential collaborations, other strategic transactions or government and other grants. Adequate capital may not be available to the Company when needed or on acceptable terms.

If the Company is unable to raise capital, it could be forced to delay, reduce, suspend, or cease its research and development programs or any future commercialization efforts, which would have a negative impact on its business, prospects, operating results and financial condition. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business.

Risks and uncertainties

The Company is subject to risks common to early-stage companies in the medical technology industry including, but not limited to, new medical and technological innovations, dependence on key personnel, protection of proprietary technology, and product liability. There can be no assurance that the Company’s products or services will be accepted in the marketplace, nor can there be any assurance that any future products or services can be developed or deployed at an acceptable cost and with appropriate performance characteristics, or that such products or services will be successfully marketed, if at all. These factors could have a materially adverse effect on the Company’s future financial results, financial position and cash flows.

Award Timing Disclosure	12 Months Ended
Award Timing Disclosure	Dec. 31, 2025
Award Tmg Disc Line Items
Award Timing MNPI Considered [Flag]	false

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities
Net loss	$ (12,150)	$ (24,830)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization of deferred financing costs	18	102
Change in fair value of convertible notes (issued, converted and outstanding)	0	6,145
Change in fair value of liability classified warrants (exercised and outstanding)	(32)	697
Shares issued for the standby equity purchase agreement commitment fee	298	0
Stock-based compensation	624	887
Change in operating assets and liabilities
Accounts receivables, net	(125)	(112)
Inventory	(66)	0
Prepaid expenses	538	297
Other assets	314	313
Accounts payable	(2,098)	(1,281)
Accrued expenses	(920)	1,875
Other liabilities	0	(100)
Net cash used in operating activities	(13,599)	(16,007)
Cash flows from financing activities
Proceeds from issuance of convertible notes	0	979
Payment of convertible notes	0	(700)
Proceeds from issuance of shares, net of offering costs	16,126	17,441
Proceeds from exercise of warrants	1,815	853
Proceeds from pre-funded warrants	5,886	3,766
Proceeds from issuance of notes payable	767	713
Payment of notes payable	(834)	(5,402)
Net cash provided by financing activities	23,760	17,650
Net increase in cash	10,161	1,643
Cash, beginning of year	1,819	176
Cash, end of year	11,980	1,819
Supplemental disclosure of cash flow information
Cash paid for interest	0	553
Cash paid for income taxes	3	3
Exercise of liability classified warrants	0	3,106
Offering cost incurred but not paid	0	45
Issuance of convertible note warrants	0	586
Board Compensation in Lieu of Cash [Member]
Supplemental disclosure of cash flow information
Board compensation settled in shares of common stock in lieu of cash	0	210
Conversion of Notes into Common Stock [Member]
Supplemental disclosure of cash flow information
Shares issued from conversion of convertible notes	$ 0	$ 10,210

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Allowance for credit losses	$ 3	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	450,000,000	500,000,000
Common stock, issued (in shares)	3,844,613	650,639
Common stock, outstanding (in shares)	3,844,613	650,639

Note 3 - Revenues and Contract Obligations (Tables)

12 Months Ended

Dec. 31, 2025

Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]

	*Year Ended December 31,*
($ in thousands)	*2025*		*2024*
Contract liabilities, beginning of period	$	—	$	100
Consideration received		—		450
Consideration refunded		—		(550	)
Contract liabilities, end of period	$	—	$	—

Note 16 - Subsequent Events

12 Months Ended

Dec. 31, 2025

Subsequent Events [Text Block]

Note 16. Subsequent Events

At-the-Market Offering

From January 2, 2026, through March 13, 2026, the Company raised approximately $0.1 million in gross proceeds ($0.1 net of offering fees) from the sale of 18,880 shares of the Company’s common stock through its At-the-Market offering program. Since the initial shelf-registration in August 2024, the Company has, as of the date of this filing, raised approximately $10.8 million in gross proceeds under the At-the-Market offering program, issuing approximately 10.7 million shares, for net proceeds of approximately $10.4 million.

Standby Equity Purchase Agreement

From January 2, 2026, through March 13, 2026, the Company raised approximately $0.3 million in gross proceeds ($0.3 million net of offering fees) from the sale of 130,184 shares of the Company’s common stock through its standby equity purchase agreement facility. Since the initial registration in May 2025, the Company has, as of the date of this filing, raised approximately $0.4 million in gross proceeds under the standby equity purchase agreement, issuing 138,184 shares, for net proceeds of approximately $0.3 million.

Nasdaq Decision Letter

On January 20, 2026, the Company received a letter from Nasdaq confirming that the Company has regained compliance with the minimum bid price requirement of the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule").

Note 8 - Warrants

12 Months Ended

Dec. 31, 2025

Warrants Disclosure [Text Block]

Note 8. Warrants

The Company has the following warrants outstanding at December 31, 2025 and 2024:

	December 31, 2025		December 31, 2024
*Liability Classified Warrants*
Private Placement Warrants		22,952		22,952
PIPE Investor Warrants		2,000		2,000
*Subtotal*		24,952		24,952

*Equity Classified Warrants*
August 2025 Warrants		530,779		—
July 2025 Warrants		560,944		—
June 2025 Warrants		994,616		—
February 2025 Warrants		377,648		—
July 2024 Warrants		101,422		101,422
January 2024 Warrants		67,213		67,213
Public Stockholders’ Warrants		42,200		42,200
Legacy Warrants		150		196
*Subtotal*		2,674,972		211,031
*Grand Total*		2,699,924		235,983

The following tables provides the weighted average strike price and time to maturity for each warrant tranche as of December 31, 2025 and 2024:

December 31, 2025	*Warrant Share Equivalents*		*Weighted-Average Strike Price*		*Weighted-Average Time to Expiration*
*Liability Classified Warrants*
Private Placement Warrants		22,952	$	2,875.00		1.82
PIPE Investor Warrants		2,000	$	2,875.00		1.82

*Equity Classified Warrants*
August 2025 Warrants		530,779	$	7.85		4.61
July 2025 Warrants		560,944	$	6.59		4.61
June 2025 Warrants		994,616	$	6.57		3.15
February 2025 Warrants		377,648	$	17.34		4.24
July 2024 Warrants		101,422	$	107.23		3.53
January 2024 Warrants		67,213	$	23.82		3.44
Public Stockholders’ Warrants		42,200	$	2,875.00		2.33
Legacy SeaStar Inc. Warrants		150	$	2,500.00		1.17

December 31, 2024	*Warrant Share Equivalents*		*Weighted-Average Strike Price*		*Weighted-Average Time to Expiration*
*Liability Classified Warrants*
Private Placement Warrants		22,952	$	2,875.00		2.82
PIPE Investor Warrants		2,000	$	2,875.00		2.82

*Equity Classified Warrants*
July 2024 Warrants		101,422	$	107.20		4.53
January 2024 Warrants		67,213	$	208.27		3.01
Public Stockholders’ Warrants		42,200	$	2,875.00		2.82
Legacy SeaStar Inc. Warrants		196	$	2,500.00		1.38

Below is the warrant activity for the year ended December 31, 2025, for those warrants with activity during the year ended December 31, 2025.

	*August 2025 Warrants*		*July 2025 Warrants*			*June 2025 Warrants*			*February 2025 Warrants*			*Legacy Warrants*
Outstanding as of December 31, 2024		—		—			—			—			196
Issuance		530,779		601,067			1,395,693			659,289			—
Exercised		—		(40,123	)		(401,077	)		(281,641	)		—
Forfeited / cancelled		—		—			—			—			(46	)
Outstanding as of December 31, 2025		530,779		560,944			994,616			377,648			150

During the year ended December 31, 2025, the Company recognized an unrealized gain of $32 thousand from the change in fair value of all remaining liability classified warrants.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and cash equivalents

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations of credit risk

Accounts Receivable [Policy Text Block]

Accounts Receivable

Income Tax, Policy [Policy Text Block]

Income taxes

Derivatives, Policy [Policy Text Block]

Use of Derivative Instruments

Fair Value Measurement, Policy [Policy Text Block]

Fair value option of accounting

The Company did not have any convertible notes outstanding during the year ended December 31, 2025.

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair value of financial instruments

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

Overall

Product Sales Revenue

•

Chargebacks, Government Rebates and Discounts – During the brief history of selling pediatric SCDs commercially, the Company has not agreed to chargebacks, government rebates or discounts.

•

Variable Consideration – the Company does not currently estimate a constraint on revenue recognized on product sales.

•

Cost of Goods and Service [Policy Text Block]

Cost of Goods Sold

	•	QUELIMUNE Specific Inventory – comprises raw materials used solely for the assembly of QUELIMMUNE inventory. It will be recognized to inventory as either raw materials, work-in-process, or finished goods depending on the stage of assembly. It will be charged to cost of goods sold upon shipment to a customer.

	•	Commingled Inventory – comprises raw materials that are used both for the assembly of QUELIMMUNE or adult SCDs. If used in the assembly of QUELIMMUNE, it will continue to be included in inventory as either work-in-process or finished goods depending on the stage of assembly and charged to cost of goods sold upon shipment to a customer.

	•	Adult SCD Specific Inventory – comprises raw materials used solely for the assembly of adult SCDs primarily to fulfill the demands of the NEUTRALIZE-AKI study. These supplies will be charged to research and development expense upon acquisition, until such time, that it is probable that these supplies could be assembled into adult SCD kits to be sold commercially.

Share-Based Payment Arrangement [Policy Text Block]

Stock-based compensation

Research and Development Expense, Policy [Policy Text Block]

Research and development expenses

Funded Research & Development Expense

Emerging Growth Company Status [Policy Text Block]

Emerging growth company status

Earnings Per Share, Policy [Policy Text Block]

Net loss per share attributable to common stockholders

New Accounting Pronouncements, Policy [Policy Text Block]

Recently adopted accounting standards

Recently issued accounting standards not yet adopted

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Conversion of Notes into Common Stock [Member] Common Stock [Member]	Conversion of Notes into Common Stock [Member] Additional Paid-in Capital [Member]	Conversion of Notes into Common Stock [Member] Retained Earnings [Member]	Conversion of Notes into Common Stock [Member]	Equity Offering, Including Pre-funded Warrants [Member] Common Stock [Member]	Equity Offering, Including Pre-funded Warrants [Member] Additional Paid-in Capital [Member]	Equity Offering, Including Pre-funded Warrants [Member] Retained Earnings [Member]	Equity Offering, Including Pre-funded Warrants [Member]	Standby Equity Purchase Agreement [Member] Common Stock [Member]	Standby Equity Purchase Agreement [Member] Additional Paid-in Capital [Member]	Standby Equity Purchase Agreement [Member] Retained Earnings [Member]	Standby Equity Purchase Agreement [Member]	Standby Equity Purchase Agreement Fees [Member] Common Stock [Member]	Standby Equity Purchase Agreement Fees [Member] Additional Paid-in Capital [Member]	Standby Equity Purchase Agreement Fees [Member] Retained Earnings [Member]	Standby Equity Purchase Agreement Fees [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2023																	254,520
Balance at Dec. 31, 2023																	$ 1	$ 100,863	$ (114,734)	$ (13,870)
Issuance of shares - conversion of convertible notes (in shares)	60,077
Issuance of shares - conversion of convertible notes	$ 0	$ 10,215	$ 0	$ 10,215
Issuance of shares - exercise of warrants (in shares)																	35,208
Issuance of shares - exercise of warrants																	$ 0	3,960	0	3,960
Issuance of shares - equity offering (including pre-funded warrants), net of issuance costs (in shares)					297,475
Issuance of shares - equity offering (including pre-funded warrants), net of issuance costs					$ 1	$ 21,244	$ 0	$ 21,245
Issuance of shares - stock issued for Board compensation in lieu of cash (in shares)																	1,012
Issuance of shares - stock issued for Board compensation in lieu of cash																	$ 0	210	0	210
Issuance of shares - vesting of RSUs (in shares)																	1,314
Issuance of shares - vesting of RSUs																	$ 0	0	0	0
Issuance of shares - stock issued for employee bonuses (in shares)																	1,033
Issuance of shares - stock issued for employee bonuses																	$ 0	73	0	73
Stock-based compensation																	0	814	0	814
Net loss																	$ 0	0	(24,830)	(24,830)
Balance (in shares) at Dec. 31, 2024																	650,639
Balance at Dec. 31, 2024																	$ 2	137,379	(139,564)	(2,183)
Issuance of shares - exercise of warrants (in shares)																	627,103
Issuance of shares - exercise of warrants																	$ 0	1,815	0	1,815
Issuance of shares - equity offering (including pre-funded warrants), net of issuance costs (in shares)					2,527,225				8,000				23,641
Issuance of shares - equity offering (including pre-funded warrants), net of issuance costs					$ 2	$ 21,968	$ 0	$ 21,970	$ 0	$ 42	$ 0	$ 42	$ 0	$ 298	$ 0	$ 298
Issuance of shares - vesting of RSUs (in shares)																	8,005
Issuance of shares - vesting of RSUs																	$ 0	0	0	0
Stock-based compensation																	0	624	0	624
Net loss																	$ 0		(12,150)	(12,150)
Balance (in shares) at Dec. 31, 2025																	3,844,613
Balance at Dec. 31, 2025																	$ 4	$ 162,126	$ (151,714)	$ 10,416

Note 10 - Stock-Based Compensation Awards (Tables)

12 Months Ended

Dec. 31, 2025

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Year Ended December 31,
($ in thousands)	2025		2024
Research and development	$	91	$	157
General and administrative		533		730
Total stock-based compensation	$	624	$	887

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	Options			Weighted-Average Exercise Price		Total Intrinsic Value		Weighted-Average Remaining Contractual Life (Years)
Outstanding at December 31, 2024	1,315			$	460.00	$	—	8.2
Exercised		—
Issued		—
Forfeited / cancelled		(192	)
Outstanding at December 31, 2025		1,123		$	460.00	$	—		7.2
Vested and exercisable at December 31, 2025		1,123		$	460.00	$	—		7.2

	Options			Weighted-Average Exercise Price		Total Intrinsic Value		Weighted-Average Remaining Contractual Life (Years)
Outstanding at December 31, 2024	885			$	443.00	$ —		5.5
Exercised		—
Issued		—
Forfeited / cancelled		(196	)
Outstanding at December 31, 2025		689		$	533	$	—		4.4
Vested and exercisable at December 31, 2025		689		$	533	$	—		4.4

The 2019 Omnibus Incentive Plan [Member]

Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

	Number of RSU			Weighted-Average Grant Date Fair Value (per share)
Outstanding at December 31, 2024		75		$	2,000.00
Granted		—
Vested		(75	)
Forfeited / cancelled		—
Outstanding at December 31, 2025		—		$	—

The 2022 Omnibus Equity Incentive Plan [Member]

Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

	Number of RSU			Weighted-Average Grant Date Fair Value (per share)
Outstanding at December 31, 2024		21,950		$	50.90
Granted		13,000
Vested		(8,080	)
Forfeited / cancelled		(1,000	)
Outstanding at December 31, 2025		25,870		$	30.50

Note 11 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Operating Lease, Expense	$ 75	$ 43

Note 16 - Subsequent Events (Details Textual) - USD ($) $ in Thousands	2 Months Ended	9 Months Ended	12 Months Ended	16 Months Ended	19 Months Ended
	Mar. 13, 2026	Mar. 13, 2026	Dec. 31, 2025	Dec. 31, 2025	Mar. 13, 2026
At-the-Market Agreement [Member]
Payments of Stock Issuance Costs			$ 200
Stock Issued During Period, Shares, New Issues (in shares)			900,000	1,100,000
At-the-Market Agreement [Member] \| Forecast [Member]
Proceeds from Issuance or Sale of Equity					$ 10,800
Payments of Stock Issuance Costs					$ 10,400
Stock Issued During Period, Shares, New Issues (in shares)					10,700,000
At-the-Market Agreement [Member] \| Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity	$ 100
Payments of Stock Issuance Costs	$ 100
Stock Issued During Period, Shares, New Issues (in shares)	18,880
Standby Equity Purchase Agreement [Member]
Stock Issued During Period, Value, New Issues			$ 42
Standby Equity Purchase Agreement [Member] \| Forecast [Member]
Proceeds from Issuance or Sale of Equity		$ 300
Stock Issued During Period, Shares, New Issues (in shares)		138,184
Stock Issued During Period, Value, New Issues		$ 400
Standby Equity Purchase Agreement [Member] \| Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity	$ 300
Payments of Stock Issuance Costs	$ 300
Stock Issued During Period, Shares, New Issues (in shares)	130,184

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

Note 11 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2025